Cargando…

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

CONTEXT: Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause. OBJECTIVE: We aimed to assess efficacy/safety of fezolinetant for treatment of moderate to severe VMS associated with menopause. METHODS: In this double-blind, placebo-controlled, 12-week...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Kimball A, Martin, Nancy, Nappi, Rossella E, Neal-Perry, Genevieve, Shapiro, Marla, Stute, Petra, Thurston, Rebecca C, Wolfman, Wendy, English, Marci, Franklin, Catherine, Lee, Misun, Santoro, Nanette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348473/ https://www.ncbi.nlm.nih.gov/pubmed/36734148 http://dx.doi.org/10.1210/clinem/dgad058

Ejemplares similares

OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
por: Fraser, Graeme L., et al.
Publicado: (2020)

“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms
por: Langley, Paul C
Publicado: (2023)

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
por: Santoro, Nanette, et al.
Publicado: (2020)

Association of Menopausal Vasomotor Symptoms With Increased Bone Turnover During the Menopausal Transition
por: Crandall, Carolyn J, et al.
Publicado: (2011)

Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
por: Cintron, Dahima, et al.
Publicado: (2018)

Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN
por: Thurston, Rebecca C., et al.
Publicado: (2021)

Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden
por: Nappi, Rossella E., et al.
Publicado: (2021)

Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action
por: Abdi, Fatemeh, et al.
Publicado: (2016)

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep
por: English, Marci, et al.
Publicado: (2021)

Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep
por: English, Marci, et al.
Publicado: (2021)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms
por: Singhal, Savita Rani, et al.
Publicado: (2016)

Vasomotor and physical menopausal symptoms are associated with sleep quality
por: Kim, Min-Ju, et al.
Publicado: (2018)

Psychosomatic and vasomotor symptom changes during transition to menopause
por: Augoulea, Areti, et al.
Publicado: (2019)

MON-387 Pheochromocytoma Masquerading as Vasomotor Menopausal Symptoms
por: Xhikola, Majlinda, et al.
Publicado: (2019)

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms
por: Ryu, Ki-Jin, et al.
Publicado: (2020)

Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms
por: Yang, Yihui, et al.
Publicado: (2023)

A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial
por: Barnard, Neal D., et al.
Publicado: (2023)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review
por: Utian, Wulf H
Publicado: (2005)

Investigation of the relationship between personality characteristics and vasomotor symptoms in menopausal women
por: Ghorbani, Mahboubeh, et al.
Publicado: (2016)

RANKL is a new Epigenetic Biomarker for the Vasomotor Symptom During Menopause
por: Kalkan, R, et al.
Publicado: (2020)

Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial
por: Pirotta, Marie, et al.
Publicado: (2014)

Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms
por: Lambert, Max Norman Tandrup, et al.
Publicado: (2017)

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review
por: Iliodromiti, S, et al.
Publicado: (2019)

Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
por: Pachman, Deirdre R, et al.
Publicado: (2010)

Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: an umbrella systematic review (protocol)
por: Goldstein, Karen M., et al.
Publicado: (2016)

Erratum to: Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial
por: Pirotta, Marie, et al.
Publicado: (2015)

Vasomotor menopausal disorders as a possible result of dysfunction of the microbiota-intestine-brain axis
por: Pavlovska, Oksana Mykolaivna, et al.
Publicado: (2022)

Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives
por: Khan, Saira J, et al.
Publicado: (2023)

Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey
por: DePree, Barbara, et al.
Publicado: (2023)

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
por: Fraser, Graeme L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5t2t3ujf0qtmm5mrp6fsk8t85u